https://pubmed.ncbi.nlm.nih.gov/38282047/?dopt=Abstract
Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to...
We found for the first time that plasma exosomal miR-361-3p was associated with malignant progression in BC patients. Mechanistically, exosomal miR-361-3p can...
https://pubmed.ncbi.nlm.nih.gov/41457098/
BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent...
Recent evidence highlights the significance of a new type of tumour suppressors, which are not frequently mutated but inhibited by metabolic cues in cancers....